Premium
ECONOMIC INCENTIVES AND CONTRACTS: THE USE OF PSYCHOTROPIC MEDICATIONS
Author(s) -
LING DAVINA C.,
BERNDT ERNST R.,
FRANK RICHARD G.
Publication year - 2008
Publication title -
contemporary economic policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.454
H-Index - 49
eISSN - 1465-7287
pISSN - 1074-3529
DOI - 10.1111/j.1465-7287.2007.00063.x
Subject(s) - medicaid , incentive , mental health , business , actuarial science , specialty , public economics , psychiatry , economics , medicine , health care , economic growth , microeconomics
The advent of novel psychotropic medications has revolutionized treatments for mental illnesses over the past few decades. Concurrently, changes in mental health coverage, particularly for Medicaid patients, created economic incentives for insurance carriers to shift costs and to encourage the use of psychotropic drugs. To quantify these effects, based on the framework in Griliches’ seminal study on hybrid corn, we estimate logistic diffusion models using a longitudinal data set on Medicaid drug utilization. We find that financial incentives played a significant role in encouraging use of new medications that have lower physician specialty skill requirements. ( JEL O30, O33, I18, L14)